Ascendis Pharma A/S (NASDAQ:ASND) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have been assigned an average rating of “Moderate Buy” from the eight brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $173.88.

ASND has been the topic of a number of research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $173.00 price target on shares of Ascendis Pharma A/S in a report on Friday. Wells Fargo & Company raised their price target on Ascendis Pharma A/S from $260.00 to $262.00 and gave the company an “overweight” rating in a report on Friday. Morgan Stanley reissued an “equal weight” rating and issued a $116.00 target price on shares of Ascendis Pharma A/S in a report on Monday, April 22nd. Citigroup upped their price target on shares of Ascendis Pharma A/S from $146.00 to $182.00 and gave the company a “buy” rating in a research note on Thursday, February 8th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Ascendis Pharma A/S from $167.00 to $170.00 and gave the stock an “overweight” rating in a research note on Friday.

Ascendis Pharma A/S Price Performance

Shares of ASND opened at $137.20 on Friday. The business has a fifty day moving average of $147.11 and a 200 day moving average of $127.28. The firm has a market capitalization of $7.99 billion, a P/E ratio of -14.83 and a beta of 0.54. Ascendis Pharma A/S has a one year low of $83.75 and a one year high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) EPS for the quarter, topping analysts’ consensus estimates of ($2.15) by $0.49. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 180.61%. The company had revenue of $148.62 million for the quarter, compared to analysts’ expectations of $97.02 million. Analysts expect that Ascendis Pharma A/S will post -4.15 EPS for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

Several institutional investors and hedge funds have recently modified their holdings of the stock. Raymond James Financial Services Advisors Inc. increased its stake in shares of Ascendis Pharma A/S by 53.6% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 14,990 shares of the biotechnology company’s stock valued at $1,404,000 after buying an additional 5,229 shares during the period. Brown Advisory Inc. raised its holdings in shares of Ascendis Pharma A/S by 2.7% in the 3rd quarter. Brown Advisory Inc. now owns 510,109 shares of the biotechnology company’s stock valued at $47,767,000 after purchasing an additional 13,227 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Ascendis Pharma A/S by 7.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,803 shares of the biotechnology company’s stock worth $1,293,000 after purchasing an additional 921 shares during the period. Chicago Partners Investment Group LLC boosted its stake in shares of Ascendis Pharma A/S by 21.4% during the third quarter. Chicago Partners Investment Group LLC now owns 8,850 shares of the biotechnology company’s stock valued at $771,000 after purchasing an additional 1,562 shares in the last quarter. Finally, TD Asset Management Inc increased its holdings in Ascendis Pharma A/S by 4.9% during the third quarter. TD Asset Management Inc now owns 267,360 shares of the biotechnology company’s stock valued at $25,036,000 after buying an additional 12,605 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.